Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolic acid; Prednisone
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms NOBILITY
- Sponsors Roche
- 15 Nov 2023 Results assessing B-cell recovery after the last dose of obinutuzumab presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc analysis of NOBILITY assessing kidney-related outcomes and steroid-sparing effects, presented at the ACR Convergence 2023
- 10 Nov 2023 Results of post hoc analysis of the phase II NOBILITY trial assessing whether adding obinutuzumab to standard-of-care lupus nephritis (LN) therapy could improve the likelihood of long-term preservation of kidney function and do so with less glucocorticoids published in the Arthritis and Rheumatology